AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea
- First Posted Date
- 2009-10-15
- Last Posted Date
- 2010-02-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 75
- Registration Number
- NCT00995787
- Locations
- 🇺🇸
Research Site, San Diego, California, United States
Comparison Study of a New Combination of 2 Marketed Medications (Esomeprazole and Naprosyn) Versus Naprosyn Alone
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2010-01-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT00992381
- Locations
- 🇦🇺
Research Site, Brisbane, Queensland, Australia
To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden
- First Posted Date
- 2009-10-08
- Last Posted Date
- 2013-01-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 25
- Registration Number
- NCT00991419
- Locations
- 🇺🇸
Research Site, Phoenix, Arizona, United States
Seroquel XR in Schizophrenia Relapse Prevention
Completed
- Conditions
- Schizophrenia Relapse Prevention
- First Posted Date
- 2009-10-07
- Last Posted Date
- 2010-11-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1600
- Registration Number
- NCT00990626
- Locations
- 🇭🇺
Research Site, Veszprem, Hungary
Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients
Phase 2
Completed
- Conditions
- Exercise Induced Asthma
- Interventions
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2012-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 66
- Registration Number
- NCT00989833
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
This is a Study to Determine the Antidepressant Effects of AZD6765
Phase 2
Completed
- Conditions
- Treatment Resistant Major Depressive Disorder
- Interventions
- Drug: Placebo to AZD6765
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2014-10-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22
- Registration Number
- NCT00986479
- Locations
- 🇺🇸
Research Site, Bethesda, Maryland, United States
The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2011-11-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 59
- Registration Number
- NCT00986531
- Locations
- 🇺🇸
Research Site, Philadelphia, Pennsylvania, United States
The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers
Early Phase 1
Completed
- Conditions
- HealthyMemory Impairment
- Interventions
- Drug: Placebo to match AZD8529
- First Posted Date
- 2009-09-29
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00985933
- Locations
- 🇺🇸
Research Site, New Haven, Connecticut, United States
A Study for the Assessment of the Words Used by Patients and Physicians to Express Asthma Symptoms
Completed
- Conditions
- Asthma
- First Posted Date
- 2009-09-29
- Last Posted Date
- 2009-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 696
- Registration Number
- NCT00986219
- Locations
- 🇬🇷
Research Site, Lakonia, Greece
Dapagliflozin DPPIV Inhibitor add-on Study
- First Posted Date
- 2009-09-25
- Last Posted Date
- 2014-06-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 833
- Registration Number
- NCT00984867
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom